Project Grant R41DE028212

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $304,019 to Panorama Research Incorporated to develop a novel therapeutic antibody to prevent alveolar bone loss in severe periodontitis. The research aims to identify and evaluate a panel of human anti-human OC-STAMP monoclonal antibodies, with the goal of selecting a lead candidate to potentially slow or halt the loss...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides funding to Cayman Chemical Co Inc. to develop novel small molecule pharmacotherapies that can stimulate alveolar bone regeneration for dental applications. The $306,868 grant, awarded on April 8, 2025, with a completion date of April 7, 2026, aims to create EZH2 inhibitor compounds that can induce osteogenesis and...

The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), awarded a $306,499 Project Grant to Oridivus LLC to develop an innovative oral regenerative therapy for improving wound healing in the oral cavity. The funding will be used to optimize and compare the immunoregenerative efficacy of an FTY720 nanofiber (FTY720-NF) scaffold versus platelet-rich plasma (PRP) in rodent and porcine animal models....

This Project Grant award of $565,228, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research (CFDA 93.121) program, aims to identify cell surface markers and develop strategies for harnessing periodontal ligament stem cells (PDLSCs) to induce endogenous periodontal regeneration. The research, conducted by the University of Pittsburgh from August 2024 to May 2029, seeks to characterize the human homologs of mouse...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to investigate the role of the lysine-specific demethylase 1 (LSD1) enzyme in regulating osteoclast activity and bone loss during periodontal disease. The $236,756 award to the Regents of the University of Minnesota will fund a 2-year research project to gain mechanistic insights into how LSD1...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1,019,315 Project Grant under the Oral Diseases and Disorders Research Program (CFDA 93.121) to the University of Maryland, Baltimore to develop novel tunable metformin-releasing injectable scaffolds to enhance dental pulp stem cell-based craniofacial bone regeneration. The 5-year project aims to test the central hypothesis that transplantation of OCT1-expressing dental pulp stem cells (DPSCs) encapsulated within...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $873,546 Project Grant under the Oral Diseases and Disorders Research Program (CFDA 93.121) to the University of Texas Health Science Center at Houston (UTHealth). The grant aims to develop a biomaterial-enhanced system for targeted localization of engineered probiotic bacteria (Limosilactobacillus reuteri) that secrete the anti-inflammatory cytokine interleukin-10 (IL-10) to treat experimental periodontitis. The key...

This federal Project Grant award by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $476,287 in funding to the Regents of the University of Michigan to research the role of the MERTK receptor tyrosine kinase in alveolar bone regeneration. The key focus of this project is to examine how MERTK signaling regulates alveolar bone stem cells and immune cell recruitment during the alveolar bone healing...

This federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $995,000.00 to the ADA Forsyth Institute, Inc. (doing business as The Forsyth Institute) to conduct research on the mechanisms of peroxisome proliferator-activated receptor-alpha (PPAR-α) regulation in periodontitis. The research aims to determine if PPAR-α agonist treatment can modulate macrophage polarization to...

The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $641,438 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The University of Iowa. The purpose of this 2-year award, effective May 13, 2024, is to develop and evaluate an innovative injectable chitosan hydrogel that can locally release the metabolite AKG to prevent and treat periodontitis-induced bone loss. The hydrogel is designed to simultaneously reduce bacterial infection,...